Regencell Bioscience Holdings Limited (RGC) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Regencell Bioscience Holdings Limited (NASDAQ: RGC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $6.71 (-2.19% 1D, market cap $3.40B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RGC ranks #572 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), RGC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DFTX (Definium Therapeutics Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -32.2%, cap $5.10B) and TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) posts a D+ grade (58/100 RQD, P/E N/A, ROIC 12.8%, cap $2.04B). Among the 5-stock peer group, RGC leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).
Per RGC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001829667), Regencell Bioscience Holdings Limited generated $0 in revenue, -$3.6M in net income, and -$3.3M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While RGC currently carries a cautious 38/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.86) and Max Pain ($7.05) forces dealer call-delta covering toward $72.45.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Regencell Bioscience Holdings Limited (RGC) dropped -2.19% to $6.71, trading at 3% of its 52-week range ($4.51 – $69). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Regencell Bioscience Holdings has seen its share price swing sharply in recent years, which puts fresh focus on whether the current US$7.67 level lines up with what its balance sheet and book value can support. With the
Regencell Bioscience Holdings reported full year results for the period ended June 30, 2026, with a net loss of US$11.7 million and basic loss per share from continuing operations of US$0.0237, compared with US$3.58 mill
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.
Gainers Regencell Bioscience (NASDAQ:RGC) stock increased by 30.4% to $10.58 during Thursday's regular session. The company's market cap stands at $4.0 billion. SenesTech (NASDAQ:SNES) stock rose 24.93% to
U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.
Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 203.8% to $3.19 during Tuesday's regular session. The company's market cap stands at $2.6 million. Picard Medical (AMEX:PMI) stock moved
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RGC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RGC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Regencell Bioscience Holdings Limited (RGC) ranks #572 by composite RQD confidence (38/100, grade D-) and #195 by equity capitalization ($3.40B). Within this direct 5-issuer industry benchmark cohort, RGC leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with RGC at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RGC
ACTIVE
Regencell Bioscience Holdings Limited | D- | 38/100 | — | — | — | -2.19% | $3.40B | Benchmark Subject |
| DFTX Definium Therapeutics Inc. | D+ | 52/100 | — | — | -32.2% | -4.29% | $5.10B | /dftx-vs-rgc → |
| TRLV Trulieve Cannabis Corp. Subordinate Voting Shares | D+ | 58/100 | — | 60.2% | 12.8% | -3.02% | $2.04B | /trlv-vs-rgc → |
| CRON Cronos Group Inc. Common Share | D | 51/100 | — | 42.8% | -4.5% | -1.79% | $1.24B | /cron-vs-rgc → |
| TLRY Tilray Brands Inc. | E | 20/100 | — | 28.4% | -3.9% | -4.17% | $390.2M | /tlry-vs-rgc → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), Regencell Bioscience Holdings Limited (RGC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$3.6M, operating cash flow of -$3.1M, and free cash flow of -$3.3M (+18.5% YoY). On the balance sheet, RGC closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $0 | -$3.6M | -$3.1M | -$3.3M | — | — |
| FY2024 (FY) | 2024-06-30 | $0 | -$4.3M | -$4.0M | -$4.0M | — | — |
| FY2023 (FY) | 2023-06-30 | $0 | -$5.9M | -$5.0M | -$5.0M | — | — |
As of 2026-11-02, Regencell Bioscience Holdings Limited (NASDAQ: RGC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $6.71 (-2.19% 1D, market cap $3.40B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RGC ranks #572 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), RGC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DFTX (Definium Therapeutics Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -32.2%, cap $5.10B) and TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) posts a D+ grade (58/100 RQD, P/E N/A, ROIC 12.8%, cap $2.04B). Among the 5-stock peer group, RGC leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).
Per RGC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001829667), Regencell Bioscience Holdings Limited generated $0 in revenue, -$3.6M in net income, and -$3.3M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RGC last traded at $6.71 (-2.19% on volume of 148,205 shares), positioning the stock -2.19% below its 50-day simple moving average ($6.86) and -60.60% below its 200-day simple moving average ($17.03). Across its 52-week range of $4.51 to $69.00, RGC sits at the 3.4% percentile with a 14-day RSI of 44.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.87 to $7.55).
Why RGC Stock dropped -2.19% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, RGC scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine 11/20 (ROIC 0%; FCF yield -0.1%), Whale 13F Flow 4/20 (institutional accumulation and options positioning), Insider Conviction 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are flow-related (13F and insider signals), and the cash engine is scored low because the reported ROIC is 0% and FCF yield is -0.1%, consistent with the negative reported FCF in the SEC financials. The forensic pillar is the strongest of the weak set, with an Altman Z of 2.5 and a Debt/Equity of 0.5, but a Piotroski F of 2/9 signals weak financial strength. Any upside case would have to rest on factors outside the reported cash-generation and flow data, which the source data does not supply.
Regencell Bioscience Holdings Limited is a NASDAQ-listed issuer in the Health Care sector, within the Medicinal Chemicals and Botanical Products industry, per the company profile. The profile does not describe its products, customers, or revenue model. Reported revenue is $0.0M in each of the three SEC financial periods provided. Not available in source data for further business detail.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-3.8M | $-3.6M | N/A | $-3.3M | N/A | N/A |
| FY 2024 | $0.0M | $-4.7M | $-4.3M | N/A | $-4.0M | N/A | N/A |
| FY 2023 | $0.0M | $-6.3M | $-5.9M | N/A | $-5.0M | N/A | N/A |
Per the SEC financials, the company reported zero revenue and operating losses across FY 2023–FY 2025, with operating losses narrowing from $-6.3M to $-3.8M. Per the market data, gross, operating, and net margins are each 0%, and ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Cash and debt balances are not available in source data.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Sector is Health Care and industry is Medicinal Chemicals and Botanical Products. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data.
Real-time company headlines, analyst actions, and sector developments for Regencell Bioscience Holdings Limited (RGC) • Click "Debate This Headline" to argue it in the Roar Pit below
Regencell Bioscience Holdings has seen its share price swing sharply in recent years, which puts fresh focus on whether the current US$7.67 level lines up with what its balance sheet and book value can support. With the
Regencell Bioscience Holdings reported full year results for the period ended June 30, 2026, with a net loss of US$11.7 million and basic loss per share from continuing operations of US$0.0237, compared with US$3.58 mill
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.
Gainers Regencell Bioscience (NASDAQ:RGC) stock increased by 30.4% to $10.58 during Thursday's regular session. The company's market cap stands at $4.0 billion. SenesTech (NASDAQ:SNES) stock rose 24.93% to
U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.
Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 203.8% to $3.19 during Tuesday's regular session. The company's market cap stands at $2.6 million. Picard Medical (AMEX:PMI) stock moved
Welcome to the RGC (Regencell Bioscience Holdings Limited) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medicinal Chemicals and Botanical Products. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on RGC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Regencell Bioscience Holdings Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on RGC, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $6.86 (52-wk range $4.51 - $69.00), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).